Anthropic unveiled Claude Science at an event for pharmaceutical executives, positioning it as the AI research counterpart to Claude Code. The new product autonomously executes scientific workflows with specialized tools for computational biology and drug development. Unlike general-purpose models, Claude Science integrates domain-specific capabilities to accelerate research timelines.

The launch reflects Anthropic's strategic push into AI-driven scientific discovery. The company plans to apply its own technology to develop treatments for rare diseases, leveraging machine learning to identify promising drug candidates faster than traditional methods. This represents a significant expansion of AI's role in pharmaceutical research.

Meanwhile, the US lifted restrictions on Anthropic's Mythos and Fable models after security discussions, restoring access that was previously blocked. The regulatory move follows concerns about AI's potential misuse, though Chinese competitors have already gained ground during the restrictions period.

Claude Science marks Anthropic's evolution from consumer chatbot provider to scientific research partner, directly challenging established lab automation tools with enterprise-grade AI capabilities.